Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F182112 + pomalidomide
- Development stage
- Phase 2
- Lead developer
- Shandong New Time Pharmaceutical
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
F182112 + pomalidomide is an investigational combination therapy being developed by Shandong New Time Pharmaceutical for the treatment of relapsed or refractory multiple myeloma (RRMM). F182112 is a bispecific monoclonal antibody designed to target B-cell maturation antigen (BCMA) on the surface of myeloma cells and the CD3 receptor on T cells, thereby redirecting T-cell cytotoxic activity to induce tumor cell lysis. Pomalidomide is an immunomodulatory imide drug (IMiD) that acts as a molecular glue, binding to the cereblon (CRBN) E3 ubiquitin ligase complex to promote the degradation of transcription factors such as Ikaros (IKZF1) and Aiolos (IKZF3), which enhances immune cell function and exerts direct anti-proliferative effects on myeloma cells. The combination is currently being evaluated in Phase II clinical trials for patients who have failed prior therapies, including lenalidomide and proteasome inhibitors, aiming to leverage the synergistic effects of T-cell engagement and immunomodulation.
- Other names
- F182112 plus pomalidomideF-182112 plus pomalidomideF 182112 plus pomalidomide
02
Targets
BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)CRBN (Cereblon)
Beyond the preview
Go deeper on F182112 + pomalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F182112 + pomalidomide.